Gadolinium-based contrast agents (GBCAs) have been used for contrast-enhanced magnetic resonance imaging (MRI) since 1988 with >450 million intravenous GBCA doses administered worldwide and overall have had an excellent safety record (1,2). Numerous studies have demonstrated the benefit of GBCAs for a variety of diagnostic indications including improving sensitivity and specificity for malignancy, demyelination, central nervous system malignancy, and infection (3–7). Initially, it was thought that GBCAs would be safer than iodinated contrast media for patients with kidney disease because they are less nephrotoxic at clinically administered doses (8). Although some case reports have linked AKI to GBCA administration, most cases involve patients with advanced renal disease or diabetes and with doses that exceed US Food and Drug Administration (FDA) recommendations (8).

The safety of GBCAs in patients with kidney disease came into question in 2006 when a strong association was found between the use of GBCAs in patients with severe kidney disease and the development of nephrogenic systemic fibrosis (NSF) (9–11). NSF results in fibrosis of the skin and internal organs and can be fatal. A confounding issue is that many people with severe kidney disease received multiple exposures to GBCAs and did not develop NSF. Conversely, patients with only one administration of a GBCA have developed NSF (15,16). It is unclear if this could at least partially relate to interspecies differences. Multiple factors may contribute, most notably patient-specific risk factors and the stability of the GBCA, which is a result of its molecular structure. Based on clinical reports, the most important factor appears to be severely reduced renal function. The most prevalent belief is that delayed clearance of GBCAs allows gadolinium to dissociate from the chelating agent and deposit in tissue (17), resulting in fibrous connective tissue and plaque formation. This theory was proposed in part because of the strong association of NSF with lower-stability linear nonionic GBCAs gadoversetamide and gadodiamide, and an ionic linear agent gadopentetate dimeglumine (17). These three GBCAs are now classified as “group 1” agents by the American College of Radiology (ACR) and “high-risk” agents by the Canadian Association of Radiology (CAR) (Table 1). Several studies have shown that use of these lower-stability GBCAs in patients with normal kidney function or mild-to-moderate CKD (eGFR 30–59 ml/min per 1.73 m²) is without clinically significant risk of NSF (8). However, they remain absolutely contraindicated in patients with AKI or stage 4 or 5 CKD (eGFR <30 ml/min per 1.73 m²).

After becoming aware of NSF in patients with severe renal disease and its association with GBCAs, many institutions adopted restrictive policies regarding the use of GBCAs and several studies demonstrated a significant decline in incidence of NSF (18–20). Wang et al. (21) demonstrated no new cases of NSF among 52,954 contrast-enhanced magnetic resonance examinations, including 6490 patients with an eGFR <60 ml/min per 1.73 m². A 2019 systematic review of the literature found 639 patients with biopsy-confirmed NSF were administered almost exclusively nonionic linear agents at high doses (>0.1 mmol/kg). Of these patients, only seven confirmed cases of NSF occurred after 2008 (22). The authors concluded that regulatory actions and practice changes have been effective in reducing the incidence of NSF.

The ACR has further categorized the remaining GBCAs into group 2 and group 3 agents that have few if any unconfounded cases of NSF, with group 2 GBCAs having greater published safety data in patients with severe kidney disease (23). Group 2 GBCAs include all macrocyclic agents and one newer linear ionic agent, whereas group 3 GBCAs comprises only one GBCA, which is a newer linear agent (Table 1). Both gadobenate dimeglumine (group 2) and gadodextrate disodium (group 3) have partial hepatobiliary excretion and protein binding, which may help explain their apparent lower risk of NSF.

Several studies have evaluated the safety of gadoterate meglumine in patients with acute kidney disease or CKD (19,24–25). A 2019 systematic review and meta-analysis of 2700 studies to evaluate the pooled risk of NSF in patients with stage 4 and 5 CKD who...
received group 2 GBCAs determined that the risk was likely no greater than 0.07% (26). The authors concluded that the potential diagnostic harms of withholding group 2 GBCAs for indicated examinations may outweigh the risk of developing NSF.

Gadolinium retention in the brain, bone, and soft tissues has emerged as another potential risk of GBCA administration (1,27–28), which has resulted in several lawsuits claiming effects related to gadolinium deposition. Unlike NSF, gadolinium retention occurs in patients with normal kidney function (27–28). Studies have shown that the degree of retention is dependent on the stability of the GBCA, similar to the cases of NSF. Specifically, linear nonionic agents retain more gadolinium than linear ionic agents, and linear ionic agents retain more gadolinium than macrocyclic agents (29–30). The exact clinical effects of this deposition are currently unknown. Limited patient self-reported data of nonallergic-like effects associated with GBCA exposure have been published (31–32). Forslin et al. (33) performed a prospective 18-year longitudinal cohort study in 23 subjects with multiple sclerosis (MS) exposed to GBCAs and 23 healthy age- and sex-matched control subjects who underwent unenhanced MRI. The results showed that increased signal intensity in the dentate nucleus (DN) in the patients with MS was associated with lower verbal frequency scores at neuropsychological testing (33). This group more recently published data suggesting that linear, but not macrocyclic, GBCA administration is associated with higher relaxation rates in a dose-dependent manner and that higher relaxation in certain regions is associated with cognitive impairment but not physical disability or fatigue in MS (34). Unfortunately, both studies are limited by the same confounding variable of MS pathology in the study cohorts. In distinction, Vymazal et al. (35) performed neurologic and neuropsychological testing of four patients with glioblastoma multiforme, all of whom had in excess of 50 contrast-enhanced MRI scans. They all showed increased T1 signal in the DN and globus pallidum. During follow-up for 14 years, none developed signs of neurologic or neuropsychological effects from the GBCA retention (35). Cocozza et al. (36) retrospectively evaluated 74 patients with relapsing-remitting MS and those with DN T1-weighted hyperintensity showed similar changes in the expanded disability status scale compared with subjects without DN high-signal intensity. At present, no adverse effects have been conclusively, scientifically linked to the retention of gadolinium in patients. To our knowledge, no case-controlled prospective studies have confirmed a causal link between gadolinium retention and symptoms.

Both the ACR and CAR have published guidelines on the use of GBCAs in patients with kidney disease (23,37). Both organizations recognize that MRI scans with contrast provide useful diagnostic information and that NSF, a serious and debilitating disease, has a strong association with certain GBCAs. They also recognize that effective screening of patients at greatest risk has essentially eliminated new cases of NSF. Finally, although many investigations have confirmed that free gadolinium deposition occurs in patients with all types of GBCAs, it does not have a predilection for people with impaired renal function, and the long-term effects and potential for complications have not yet been established. Ultimately, the decision whether to administer GBCAs must be made by referring physicians in consultation with radiologists to identify the most appropriate examination to answer the clinical question. The benefits of improved diagnostic accuracy must be compared with the very small, albeit not zero, risk for NSF in patients with severe kidney disease and the currently unknown clinical risk of gadolinium deposition elsewhere. The radiology community remains committed to studying the potential risks and has developed a roadmap for investigation (2). Advances in noncontrast-enhanced MRI sequences continue, however, some clinical indications still require contrast enhancement for correct interpretation (38).

GBCA use during MRI scanning has had an excellent safety record over the past three decades. Despite a probable correlation between development of NSF after the use of group 1 agents in patients with stage 4 and 5 CKD, current data supports the safe use of the group 2 agents at recommended doses in patients with AKI, CKD stage 4 or 5, or those on dialysis. Although the safety of these agents may be questioned in animal studies, the benefit of using them in making accurate and important clinical diagnoses has far outweighed the small theoretical risk of developing NSF.

### Table 1. Current or previously approved gadolinium-based contrast agents and their manufacturer, chemical structure and ionicity, American College of Radiology classification, and Canadian Association of Radiologists risk assessment

<table>
<thead>
<tr>
<th>Gadolinium Agent</th>
<th>Manufacturer</th>
<th>Chemical Structure</th>
<th>ACR Classification</th>
<th>CAR Risk Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gadodiamide</td>
<td>GE Healthcare</td>
<td>Linear nonionic</td>
<td>Group 1</td>
<td>High risk</td>
</tr>
<tr>
<td>Gadoversetamide</td>
<td>Guerbet</td>
<td>Linear nonionic</td>
<td>Group 1</td>
<td>High risk</td>
</tr>
<tr>
<td>Gadopentetate dimeglumine</td>
<td>Bayer AG</td>
<td>Linear ionic</td>
<td>Group 1</td>
<td>High risk</td>
</tr>
<tr>
<td>Gadobutrol</td>
<td>Bayer Healthcare/Bayer AG</td>
<td>Macrocyclic nonionic</td>
<td>Group 2</td>
<td>Low risk</td>
</tr>
<tr>
<td>Gadoteridol</td>
<td>Bracco Diagnostics</td>
<td>Macrocyclic nonionic</td>
<td>Group 2</td>
<td>Low risk</td>
</tr>
<tr>
<td>Gadoteram egmeline</td>
<td>Guerbet</td>
<td>Macrocyclic ionic</td>
<td>Group 2</td>
<td>Low risk</td>
</tr>
<tr>
<td>Gadobenate dimeglumine</td>
<td>Bracco Diagnostics</td>
<td>Linear ionic</td>
<td>Group 2</td>
<td>Medium risk</td>
</tr>
<tr>
<td>Gadoxetate disodium</td>
<td>Bayer Healthcare</td>
<td>Linear ionic</td>
<td>Group 3</td>
<td>Medium risk</td>
</tr>
</tbody>
</table>

ACR, American College of Radiology; CAR, Canadian Association of Radiologists.

**Author Contributions**

E. Soloff and C. Wang conceptualized the study, wrote the original draft, and reviewed and edited the manuscript.

**Disclosures**

E. Soloff and C. Wang have nothing to disclose.
References


35. Vymazal J, Krámská L, Brožová H, Růžička E, Ruseň AM: Does serial administration of gadolinium-based contrast agents affect patient neurological and neuropsychological status? Fourteen-year follow-up of patients receiving more than fifty contrast
